Related Experiment Video
Updated: Mar 11, 2026
08:46
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
54.2K
Chimeric antigen receptor T cell therapy in AML: How close are we?
1Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Room 8-101, Smilow Research Center, 3400 Civic Center Boulevard, Philadelphia, PA 19104, USA.
Best Practice & Research. Clinical Haematology
|November 29, 2016
Summary
Allogeneic hematopoietic cell transplantation (HCT) is effective for acute myeloid leukemia (AML) post-remission therapy but faces limitations. Chimeric antigen receptor (CAR) T cell therapy shows promise for AML, but challenges remain for its safe application.
Area of Science:
- Hematology
- Immunotherapy
- Oncology
Background:
- Acute myeloid leukemia (AML) requires post-remission therapy for long-term survival.
- Allogeneic hematopoietic cell transplantation (HCT) is a key T cell immunotherapy for AML.
- Current HCT efficacy is limited in patients with active disease or measurable residual disease (MRD).
Purpose of the Study:
- To explore the limitations of T cell-based immunotherapy in AML.
- To investigate the potential of Chimeric Antigen Receptor (CAR) T cell therapy for AML treatment.
- To identify challenges hindering CAR T cell therapy application in AML.
Main Methods:
- Review of current T cell immunotherapy strategies for AML.
- Analysis of the efficacy and limitations of allogeneic HCT.
- Exploration of CAR T cell therapy principles and challenges in the context of AML.
Main Results:
- Allogeneic HCT effectiveness diminishes in the presence of measurable residual disease (MRD) or active AML.
- T cell efficacy in HCT is constrained by the need to avoid graft-versus-host disease (GVHD).
- CAR T cell therapy, successful in B-cell malignancies, presents potential but faces significant hurdles for AML application.
Conclusions:
- Limitations in current T cell immunotherapies necessitate novel approaches for AML.
- CAR T cell therapy offers a potential alternative for AML treatment.
- Overcoming challenges is crucial for the safe and effective clinical implementation of CAR T cell therapy in AML.
